Menquadfi

— THERAPEUTIC DISORDERS TREATED —
  • Vaccines

Menquadfi Generic Name & Formulations

General Description

Neisseria meningitidis polysaccharide antigens (conjugated to approx. 55mcg of tetanus toxoid protein carrier); 10mcg each of Group A, C, W, and Y; per 0.5mL; soln for IM inj; preservative-free.

Pharmacological Class

Meningitis vaccine.

How Supplied

Single-dose vials—5

Manufacturer

Generic Availability

NO

Menquadfi Indications

Indications

Meningitis immunization.

Menquadfi Dosage and Administration

Adults and Children

<2yrs: not established. Give by IM inj only. Primary vaccination: ≥2yrs: 0.5mL once as single inj. Booster vaccination: ≥15yrs: may give a single (0.5mL) dose for those at continued risk, if at least 4yrs have elapsed since the prior dose.

Menquadfi Contraindications

Contraindications

Severe allergic reaction after a previous dose of MenQuadfi or any other tetanus toxoid-containing vaccine.

Menquadfi Boxed Warnings

Not Applicable

Menquadfi Warnings/Precautions

Warnings/Precautions

Not for the prevention of N. meningitidis serogroup B disease. Not a substitute for routine tetanus immunization. Have epinephrine inj (1:1000) available. History of Guillain-Barre syndrome. Immunosuppressed. Complement deficiency. Eculizumab therapy. Risk of syncope. Pregnancy. Nursing mothers.

Menquadfi Pharmacokinetics

See Literature

Menquadfi Interactions

Interactions

Immunosuppressants may get suboptimal response. Concomitant other vaccines: see full labeling.

Menquadfi Adverse Reactions

Adverse Reactions

Inj site reactions (pain, erythema, swelling), myalgia, headache, malaise.

Menquadfi Clinical Trials

See Literature

Menquadfi Note

Notes

To enroll pregnant patients or obtain information call (800) 822-2463.

Menquadfi Patient Counseling

See Literature

Images